POSTOPERATIVE SURVIVAL RESULTS OF PATIENTS WITH STAGE I-II MALIGNANT PLEURAL MESOTHELIOMA IN AN ENDEMIC AREA
Introduction: The accepted treatment option for malignant pleural mesothelioma (MPM) is multimodality treatment including surgery, chemotherapy and radiotherapy. In this study, we aimed to evaluate the results of patients who underwent surgical resection for multimodality treatment due to MPM at our clinic between July 2015 and October 2019.
Method: The results of 13 patients who underwent surgical treatment for MPM in our clinic were evaluated retrospectively. Patients' demographic structure, regions where they live, symptom presentation, disease localization, biopsy diagnosis, type of surgical treatment, choice of neoadjuvant or adjuvant chemotherapy, postoperative complications and survival outcomes were evaluated.
Results:The mean survival time was 19.6 months. Six patients were still under follow-up. One patient whose postoperative pathology was reported as mixed type had the worst survival with 13 months and the best survival was 32 months in the patient who underwent postoperative hyperthermic chemotherapy with pleural decortication. Four patients died due to local recurrence and general condition disorder, and two patients died after peritonitis carcinomatosis and ascites.
Conclusion: Epitheloid type multimodality treatment and intrapleural hyperthermic chemotherapy may be a good choice in patients with the stage I and II malignant mesothelioma without surgical comorbidity.
Senyigit A, Coskunsel M, Topcu F, Isık R, Babayigit C. Malignant pleural mesothelioma: evaluation of clinical, radiological and histological features in 136 cases. Tuberkuloz ve Toraks Dergisi. 2000; 48(1): 26-34.
Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest. 2002; 122(6): 2224-9.
Turk F, Yuncu G, Ozturk G. Mezotelyomada tani ve tedavi amacli cerrahi yaklasimlar. Pam Med J. 2012; 5(3): 105-9.
Kang SR, Bok JS, Lee GD, Choi SH, Kim HR, Kim DK, et. al. Surgical options for malignant mesothelioma: a single-center experience. Korean J Thorac Cardiovasc Surg. 2018; 51(3): 195-201.
Bozlar U, Ors F, Yildirim D, Battal B, Saglam M, Nural MS. Atypical malignant mesothelioma characterized with massive effusion: computed tomography findings. Firat Med J. 2009; 14(1): 78-80.
Sugarbaker PH. Intra-abdominal manifestations of pleural mesothelioma. Ann Transl Med. 2017; 5(11): 231.
Waller DA. Lung-sparing total pleurectomy: the surgical option of choice in malignant pleural mesothelioma? Eur J Cardiothorac Surg. 2013; 44(1): 123-4.
Tanrikulu AC, Abakay O, Sezgi C,Sen HS, Abakay A. Comparison of supportive treatment and pleurodesis in patients with malignant pleural mesothelioma. Dicle Med J. 2012; 39(4): 509-12.
Armato SG 3rd, Francis RJ, Katz SI, Ak G, Opitz I, Gudmundsson E, et. al. Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer. 2019; 130: 108-14.
Lovrenski A, Panjkovic M, Tegeltija D, Latinovic LT, Krcedinac J. The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma. Med Pregl. 2012; 65(1-2): 5-8.
Eren S, Balci AE, Ulku R, Esme H, Eren MN. Role of Video-Assisted Thoracoscopic Surgery (VATS) in pleural effusions. Tuberk Toraks. 2002; 50(1): 53-8.
MacRae RM, Ashton M, Lauk O, Wilson W, O'Rourke N, Simone CB 2nd, et. al. The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group. Lung Cancer. 2019; 132: 24-7.
Schröder C, Opitz I, Guckenberger M, Stahel R, Weder W, Förster R, et.al. Stereotactic Body Radiation Therapy (SBRT) as salvage therapy for oligorecurrent pleural mesothelioma after multi-modality therapy. Front Oncol. 2019; 9: 961.
Noiret B, Eveno C. Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma. Pleura Peritoneum. 2019; 4(2): 20190011.
Franceschini D, De Rose F, Cozzi S, Renna I, Franzese C, Di Brina L, et. al. Volumetric modulated arc therapy after lung sparing surgery for malignant pleural mesothelioma: a single institution experience. Clin Lung Cancer. 2020; 21(1): 86-93.
Tokat AO, Kutlay H. Gene therapy in malignant mesothelioma. Tuberk Toraks. 2003; 51(4): 456-60.
Hassan M, Mercer RM, Maskell NA, Asciak R, McCracken DJ, Bedawi EO, et. al. Survival in patients with malignant pleural effusion undergoing talc pleurodesis. Lung Cancer. 2019; 137: 14-8.
Kai Y, Tsutani Y, Tsubokawa N, Ito M, Mimura T, Miyata Y, et. al. Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma. Oncol Lett. 2019; 17(3): 3607-14.
Rokicki W, Rokicki M, Wojtacha J, Rydel MK. Malignant mesothelioma as a difficult interdisciplinary problem. Kardiochir Torakochirurgia Pol. 2017; 14(4): 263-7.
Scherpereel A, Astoul P, Bass P, Berghmans T, Clayson H, de Vuyst P, et. al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010; 35(3): 479-95.
Hasegawa S. Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg. 2014; 62(9): 516-21.
Opitz I, Weder W. A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Transl Med. 2017; 5(11): 237.
Kostron A, Friess M, Inci I, Hillinger S, Schneiter D, Gelpke H, et. al. Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients. Interact Cardiovasc Thorac Surg. 2017; 24(5): 740-6.
Shahin Y, Wellham J, Jappie R, Pointon K, Majewski A, Black E. How successful is lung-preserving radical surgery in the mesothelioma and radical surgery-trial environment? A case-controlled analysis. Eur J Cardiothorac Surg. 2011; 39(3): 360-3.
Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006; 24(10):1561-7.
Ambrogi MC, Bertoglio P, Aprile V, Chella A, Korasidis S, Fontanini G, et. al. Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience. J Thorac Cardiovasc Surg. 2018; 155(4): 1857-66.
Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, et.al. A phase I trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma. J Thorac Oncol. 2018; 13(9): 1400-9.
- There are currently no refbacks.
Copyright (c) 2020 Tayfun Kermenli
This work is licensed under a Creative Commons Attribution 4.0 International License.